HHS and FDA unveil draft "plausible mechanism" pathway to speed individualized rare‑disease therapies

HHS Secretary Robert F. Kennedy Jr. announced that the Food and Drug Administration has released draft guidance establishing a new approval pathway for individualized therapies for rare genetic diseases called the "plausible mechanism" framework. "The FDA releases draft guidance establishing a new pathway to approval individualized for individualized therapy for rare genetic disorders, and we're calling this the plausible mechanism framework," Kennedy said, and added that the administration would "insist on transparency" and "require long term safety monitoring."

The framework, officials said, is aimed at conditions for which randomized controlled trials are often infeasible. "For ultra rare conditions, randomized controlled trials are often and mostly always just not feasible," Kennedy said, and the draft guidance would permit "one well controlled clinical investigation supported by confirmatory evidence" to support approval. FDA Commissioner Marty McCary framed the policy as part of broader steps to help small populations: "30,000,000 Americans have a rare disease. That's 1 in 11 people in our country," he said, and described new manufacturing flexibilities and use of Bayesian methods as complementary changes.

Tracy Beth Hogue, acting director of the FDA's Center for Drug Evaluation and Research, said the guidance focuses on treatments that target a clearly defined molecular, cellular or genetic basis and produce clinical or biochemical responses inconsistent with the natural history of the disease. "The plausible mechanism pathway is a way for treatments to get a special path to approval that uses the same standards for FDA approval as we've already used," Hogue said, noting the guidance explicitly lists antisense oligonucleotides and is intended to be cross‑center (CDER and CBER).

Researchers who developed the first individualized CRISPR therapy for baby "KJ" described the scientific approach that inspired the policy. Kieran Musonoru of the University of Pennsylvania said his team adapted a genetic therapy platform — by changing what he described as the therapy's "GPS address" — to correct KJ's CPS1 gene mutation with support from the National Institutes of Health and close coordination with FDA reviewers. Musonoru said the approach could support an umbrella trial for related liver‑centered disorders. "We were able to take that same heart disease genetic therapy, just change the GPS address to point the therapy to KJ's broken gene," he said.

Parents and advocates at the event urged that the pathway be implemented in ways that protect patients and preserve data transparency. Judy Stecker, whose son Wheeler has CLN3, described the burdens families shoulder to reach experimental treatments and called for the new framework to translate individual acts of advocacy into scalable access. "This framework creates a commercially viable path to deliver hope, not one child at a time, but at scale," Stecker said.

Reporters pressed officials in a question‑and‑answer session about scope and oversight. When asked whether the administration was "embracing genome editing and...not embracing mRNA vaccines," Commissioner McCary replied that the FDA has approved mRNA vaccines and that funding choices reflected where public dollars were most needed: "the companies that made mRNA vaccines made over $50,000,000,000. They can fund their own research."

On procedural questions, Hogue said the draft guidance is intentionally open‑ended on an "ultra rare" cutoff and can apply to non‑editing modalities if the mechanistic and evidentiary criteria are met; she pointed to a recent CDER approval for Menkes disease (Xikubo) as an example of using nonrandomized evidence. Hogue also explained reviewers in CBER and CDER will conduct the work and that individual INDs will likely be required under umbrella protocols that allow related INDs to move into combined phase‑2/3 trials.

Officials repeatedly emphasized safeguards: they said approvals would still require rigorous evidence, long‑term safety monitoring and transparency about outcomes and that real‑world evidence will be accepted but evaluated for quality. The event closed with officials inviting families, researchers and industry to work together to implement the guidance and with a final group photograph.

Next steps: the FDA's draft guidance is being released for public review and comment; the transcript indicates HHS and FDA expect to receive numerous applications and to update review processes accordingly.